45.11
-0.227(-0.50%)
Currency In USD
| Previous Close | 45.34 |
| Open | 45.26 |
| Day High | 45.27 |
| Day Low | 44.68 |
| 52-Week High | 45.91 |
| 52-Week Low | 29.66 |
| Volume | 1.97M |
| Average Volume | 4.07M |
| Market Cap | 19.33B |
| PE | 25.34 |
| EPS | 1.78 |
| Moving Average 50 Days | 40.42 |
| Moving Average 200 Days | 37.09 |
| Change | -0.23 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $1,111.47 as of February 19, 2026 at a share price of $44.848. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 5 years ago, it would be worth $1,029.57 as of February 19, 2026 at a share price of $44.848.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
GlobeNewswire Inc.
Jan 20, 2026 9:15 PM GMT
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The co
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
GlobeNewswire Inc.
Jan 11, 2026 10:15 PM GMT
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of v
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
GlobeNewswire Inc.
Dec 29, 2025 9:40 PM GMT
Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portio